Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) – Stock analysts at Leerink Swann dropped their FY2017 earnings per share estimates for shares of Vertex Pharmaceuticals in a research report issued to clients and investors on Friday. Leerink Swann analyst G. Porges now anticipates that the firm will earn $1.73 per share for the year, down from their prior estimate of $1.95. Leerink Swann currently has a “Outperform” rating on the stock.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.03. The company earned $431.61 million during the quarter, compared to analysts’ expectations of $428.08 million. Vertex Pharmaceuticals had a negative return on equity of 12.34% and a negative net margin of 17.77%. The firm’s quarterly revenue was up 159.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.54) EPS.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded Vertex Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 27th. Jefferies Group restated a “buy” rating and issued a $103.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, June 17th. Citigroup Inc. initiated coverage on Vertex Pharmaceuticals in a research report on Tuesday, September 13th. They issued a “market perform” rating for the company. They noted that the move was a valuation call. Credit Suisse Group AG restated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, June 16th. Finally, Vetr upgraded Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $94.50 target price for the company in a research report on Monday, June 27th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $117.60.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 85.70 on Monday. The stock’s market capitalization is $21.23 billion. Vertex Pharmaceuticals has a one year low of $75.90 and a one year high of $134.71. The firm has a 50-day moving average price of $92.75 and a 200 day moving average price of $89.81.

In related news, Director Joshua S. Boger sold 6,500 shares of the stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $87.44, for a total value of $568,360.00. Following the completion of the sale, the director now owns 274,725 shares in the company, valued at $24,021,954. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Stuart A. Arbuckle sold 1,208 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $86.46, for a total transaction of $104,443.68. Following the completion of the sale, the executive vice president now owns 114,566 shares of the company’s stock, valued at approximately $9,905,376.36. The disclosure for this sale can be found here. Company insiders own 1.90% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Edmond DE Rothschild Holding S.A. boosted its position in shares of Vertex Pharmaceuticals by 44.8% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 188,514 shares of the pharmaceutical company’s stock worth $14,985,000 after buying an additional 58,300 shares in the last quarter. Scotia Capital Inc. boosted its position in shares of Vertex Pharmaceuticals by 243.8% in the first quarter. Scotia Capital Inc. now owns 9,541 shares of the pharmaceutical company’s stock worth $759,000 after buying an additional 6,766 shares in the last quarter. Lazard Asset Management LLC boosted its position in shares of Vertex Pharmaceuticals by 23.1% in the first quarter. Lazard Asset Management LLC now owns 960,230 shares of the pharmaceutical company’s stock worth $76,327,000 after buying an additional 180,389 shares in the last quarter. Rafferty Asset Management LLC boosted its position in shares of Vertex Pharmaceuticals by 28.9% in the first quarter. Rafferty Asset Management LLC now owns 9,438 shares of the pharmaceutical company’s stock worth $750,000 after buying an additional 2,114 shares in the last quarter. Finally, BB&T Securities LLC boosted its position in shares of Vertex Pharmaceuticals by 11.0% in the first quarter. BB&T Securities LLC now owns 5,960 shares of the pharmaceutical company’s stock worth $473,000 after buying an additional 591 shares in the last quarter. Institutional investors and hedge funds own 96.19% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.